Literature DB >> 16855177

Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats.

Ashraf Yassen1, Jingmin Kan, Erik Olofsen, Ernst Suidgeest, Albert Dahan, Meindert Danhof.   

Abstract

The purpose of this investigation was to develop a mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) model to predict the time course of respiratory depression following administration of opioids in rats. The proposed model is based on receptor theory and aims at the separate characterization of biophase distribution and receptor association/dissociation kinetics as determinants of hysteresis between plasma concentration and effect. Individual concentration time courses of buprenorphine and fentanyl were determined in conjunction with continuous monitoring of respiratory depression. Buprenorphine and fentanyl were administered intravenously in various doses. For buprenorphine hysteresis was best described by a combined biophase distribution-receptor association/dissociation model with a linear transducer function. The values of the parameter estimates of the rate constants for biophase distribution (k(eo)), receptor association (k(on)), and dissociation (k(off)) were 0.0348 min(-1) [95% confidence interval (CI), 0.0193-0.0503 min(-1)], 0.57 ml/ng/min (95% CI, 0.38-0.76 ml/ng/min), and 0.0903 min(-1) (95% CI, 0.035-0.196 min(-1)), respectively. The values of the equilibrium dissociation constant and intrinsic activity were 0.16 ng/ml and 0.48 (95% CI, 0.45-0.51), respectively. The value of the K(d) is close to reported estimates of receptor affinity in vitro confirming the validity of the mechanism-based PK/PD model. For fentanyl, unrealistically high estimates of the rate constants for receptor association and dissociation were obtained, indicating that hysteresis is caused solely by biophase distribution kinetics. This is consistent with fentanyl's fast receptor association/dissociation kinetics in vitro. As a result, the mechanism-based PK/PD model of fentanyl could be reduced to a biophase distribution model with fractional sigmoid E(max) pharmacodynamic model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16855177     DOI: 10.1124/jpet.106.107953

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach.

Authors:  Esther Encinas; Rosario Calvo; John C Lukas; Valvanera Vozmediano; Monica Rodriguez; Elena Suarez
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

2.  CrossTalk opposing view: The pre-Botzinger complex is not essential for respiratory depression following systemic administration of opioid analgesics.

Authors:  Peter M Lalley; Paul M Pilowsky; Hubert V Forster; Edward J Zuperku
Journal:  J Physiol       Date:  2014-03-15       Impact factor: 5.182

3.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.

Authors:  Martin Johnson; Magdalena Kozielska; Venkatesh Pilla Reddy; An Vermeulen; Cheryl Li; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2011-06-07       Impact factor: 4.200

Review 4.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

Review 5.  Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial.

Authors:  Tianjing Ren; Xu Zhu; Natalie M Jusko; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-08-30       Impact factor: 2.410

6.  A physiologically-based recirculatory meta-model for nasal fentanyl in man.

Authors:  Richard N Upton; David J R Foster; Lona L Christrup; Ola Dale; Kristin Moksnes; Lars Popper
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-19       Impact factor: 2.745

7.  Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.

Authors:  Ashraf Yassen; Erik Olofsen; Eveline van Dorp; Elise Sarton; Luc Teppema; Meindert Danhof; Albert Dahan
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats.

Authors:  Ashraf Yassen; Erik Olofsen; Jingmin Kan; Albert Dahan; Meindert Danhof
Journal:  Pharm Res       Date:  2007-10-04       Impact factor: 4.200

9.  Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine.

Authors:  Ashraf Yassen; Erik Olofsen; Jingmin Kan; Albert Dahan; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 10.  Translational PK-PD modeling in pain.

Authors:  Ashraf Yassen; Paul Passier; Yasuhisa Furuichi; Albert Dahan
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.